Format

Send to

Choose Destination
Cancer Res. 2018 Jul 1;78(13):3709-3717. doi: 10.1158/0008-5472.CAN-18-0161. Epub 2018 May 14.

NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.

Author information

1
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
2
Shandong Provincial Hospital affiliated to Shandong University, Jinan, China.
3
Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
4
Acetylon Pharmaceuticals, Inc., Boston, Massachusetts.
5
Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. kwok-kin.wong@nyumc.org.

Abstract

Small-cell lung cancer (SCLC) has the highest malignancy among all lung cancers, exhibiting aggressive growth and early metastasis to distant sites. For 30 years, treatment options for SCLC have been limited to chemotherapy, warranting the need for more effective treatments. Frequent inactivation of TP53 and RB1 as well as histone dysmodifications in SCLC suggest that transcriptional and epigenetic regulations play a major role in SCLC disease evolution. Here we performed a synthetic lethal screen using the BET inhibitor JQ1 and an shRNA library targeting 550 epigenetic genes in treatment-refractory SCLC xenograft models and identified HDAC6 as a synthetic lethal target in combination with JQ1. Combined treatment of human and mouse SCLC cell line-derived xenograft tumors with the HDAC6 inhibitor ricolinostat (ACY-1215) and JQ1 demonstrated significant inhibition of tumor growth; this effect was abolished upon depletion of NK cells, suggesting that these innate immune lymphoid cells play a role in SCLC tumor treatment response. Collectively, these findings suggest a potential new treatment for recurrent SCLC.Significance: These findings identify a novel therapeutic strategy for SCLC using a combination of HDAC6 and BET inhibitors. Cancer Res; 78(13); 3709-17. ©2018 AACR.

PMID:
29760044
PMCID:
PMC6450092
DOI:
10.1158/0008-5472.CAN-18-0161
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center